Skip to main content

T-cell stimulation could be used to target cancers with common TP53 gene mutations

*January 2020*

Researchers in the Center for Cancer Research have found that circulating lymphocytes can be stimulated in the laboratory to generate cells that can recognize TP53 gene mutations. Mutations to the TP53 gene are found in about 40 percent of all cancers, making this process a potentially significant step forward in fighting many types of cancer. The research, conducted by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, Parisa Malekzadeh, M.D., Drew C. Deniger, Ph.D., and colleagues appeared January 29, 2020, in Clinical Cancer Research. Read more.